Atomica Launches Biotechnology Microdevices Platform

SANTA BARBARA, Calif., Oct. 6, 2026 /CourierPR/ -- Atomica, a U.S.-based microfabrication foundry, has unveiled its latest platform, the Biotechnology Microdevices Platform, designed to accelerate the development of diagnostic, drug delivery, and medical research devices. This new platform, the seventh in Atomica’s portfolio, aims to bridge the gap between innovative ideas and practical applications, bringing healthcare technologies to market faster.

The Biotechnology Microdevices Platform combines established microfabrication modules with custom design flexibility and engineering collaboration. This approach supports customers from the initial feasibility stage through scalable production, addressing the engineering and manufacturing challenges that often delay the development of promising healthcare technologies.

The platform supports a range of diagnostic technologies, including compact chips used in testing cartridges for cancer, infectious diseases, and genetic analysis. These devices integrate sample preparation and detection functions, enabling developers to bring more testing to clinics and other points of need, where timely answers can guide care.

For drug delivery, the platform supports the development of microneedle arrays and related structures for minimally invasive delivery and sampling. These components can be combined with reservoirs and fluid controls in devices designed to reduce the burden of conventional administration and support new approaches to treatment.

The platform also facilitates the tools behind future therapies, such as cell-analysis chips, microarrays, and organ-on-chip systems, which allow researchers to study biological responses in controlled environments. Additionally, wearable and implantable sensing structures extend the platform’s applications into medical monitoring.

Atomica’s Biotechnology Microdevices Platform spans five device families: microfluidics, microneedles, microarrays, sensors and diaphragms, and packaging and integration. Customers can build on established processes and add features suited to their diagnostic method, therapy, or research application. This foundation helps reduce the process development work required while preserving room for product innovation.

The platform’s comprehensive support extends from feasibility work and engineering samples through functional prototypes, qualification, and scalable production. Atomica’s engineers collaborate closely with customers to evaluate fabrication, packaging, testing, and connections to the rest of the product. Addressing these requirements early helps avoid costly redesigns and delays as devices move beyond the laboratory.

The launch of the Biotechnology Microdevices Platform expands Atomica’s portfolio, joining other recently launched platforms such as AI Optical Connectivity, AI Optical Source, AI Photonic Integration, AI Thermal Microstructures, Physical AI Sensor, and MEMS Optical Control. Together, these platforms provide customers with access to established microfabrication capabilities tailored to the needs of advanced hardware applications.